Treatment strategies for patients with diffuse large B-cell lymphoma
S Poletto, M Novo, L Paruzzo, PMM Frascione… - Cancer treatment …, 2022 - Elsevier
Diffuse large B-cell lymphoma (DLBCL) is nowadays a curable disease with the frontline
treatment R-CHOP, but 30–40% of patients are still unresponsive or relapse thereafter. In …
treatment R-CHOP, but 30–40% of patients are still unresponsive or relapse thereafter. In …
A comprehensive overview on antibody-drug conjugates: from the conceptualization to cancer therapy
F Riccardi, M Dal Bo, P Macor, G Toffoli - Frontiers in Pharmacology, 2023 - frontiersin.org
Antibody-Drug Conjugates (ADCs) represent an innovative class of potent anti-cancer
compounds that are widely used in the treatment of hematologic malignancies and solid …
compounds that are widely used in the treatment of hematologic malignancies and solid …
Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial
Axicabtagene ciloleucel (axi-cel) demonstrated superior efficacy compared to standard of
care as second-line therapy in patients with high-risk relapsed/refractory (R/R) large B cell …
care as second-line therapy in patients with high-risk relapsed/refractory (R/R) large B cell …
Follicular lymphoma: 2023 update on diagnosis and management
E Jacobsen - American Journal of Hematology, 2022 - Wiley Online Library
Abstract Disease Overview Follicular lymphoma (FL) is generally an indolent B cell
lymphoproliferative disorder of transformed follicular center B cells. FL is characterized by …
lymphoproliferative disorder of transformed follicular center B cells. FL is characterized by …
Recent bendamustine treatment before apheresis has a negative impact on outcomes in patients with large B-cell lymphoma receiving chimeric antigen receptor T-cell …
G Iacoboni, V Navarro, AÁ Martín-López… - Journal of Clinical …, 2024 - ascopubs.org
PURPOSE Approximately 30%-40% of patients with relapsed/refractory (R/R) large B-cell
lymphoma (LBCL) infused with CD19-targeted chimeric antigen receptor (CAR) T cells …
lymphoma (LBCL) infused with CD19-targeted chimeric antigen receptor (CAR) T cells …
2024 Update: Advances in the risk stratification and management of large B‐cell lymphoma
M Tavakkoli, SK Barta - American Journal of Hematology, 2023 - Wiley Online Library
Diffuse large B‐cell lymphoma (DLBCL) is a heterogeneous disease with varying clinical
outcomes. Our understanding of its molecular makeup continues to improve risk …
outcomes. Our understanding of its molecular makeup continues to improve risk …
A multicenter retrospective study of polatuzumab vedotin in patients with large B-cell lymphoma after CAR T-cell therapy
S Gouni, AC Rosenthal, JL Crombie, A Ip… - Blood …, 2022 - ashpublications.org
Polatuzumab vedotin (PV) is an antibody–drug conjugate targeting CD79b that is approved
for patients with relapsed/refractory large B-cell lymphoma (LBCL). Patients who relapse …
for patients with relapsed/refractory large B-cell lymphoma (LBCL). Patients who relapse …
Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial
Y Song, H Tilly, S Rai, H Zhang, J Jin, H Goto, Y Terui… - Blood, 2023 - ashpublications.org
In the phase 3 POLARIX study in previously untreated diffuse large B-cell lymphoma,
polatuzumab vedotin combined with rituximab plus cyclophosphamide, doxorubicin, and …
polatuzumab vedotin combined with rituximab plus cyclophosphamide, doxorubicin, and …
Novel precision medicine approaches and treatment strategies in hematological malignancies
R Rosenquist, E Bernard, T Erkers… - Journal of Internal …, 2023 - Wiley Online Library
Genetic testing has been applied for decades in clinical routine diagnostics of hematological
malignancies to improve disease (sub) classification, prognostication, patient management …
malignancies to improve disease (sub) classification, prognostication, patient management …
Sequencing therapy in relapsed DLBCL
CR Flowers, OO Odejide - Hematology, 2022 - ashpublications.org
Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoid malignancy
worldwide, comprising approximately 30% of all lymphomas. Currently, 50% to 60% of …
worldwide, comprising approximately 30% of all lymphomas. Currently, 50% to 60% of …